Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Tavokinogene telsaplasmid (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors OncoSec Medical
- 27 Sep 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 27 Sep 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated